(Q38148222)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Targeting ribonucleotide reductase for cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Jimin Shao

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Lijun Zhu

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Yun Yen

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

language of work or name

English

0 references

publication date

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

26 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

1423-1437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083455%20AND%20SRC:MED&resulttype=core&format=json

Ribonucleotide reductases

26 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Class I ribonucleotide reductases: metallocofactor assembly and repair in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase inhibitors and future drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Structure of ribonucleotide reductase protein R1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Three-dimensional structure of the free radical protein of ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Structure and function of the Escherichia coli ribonucleotide reductase protein R2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Structural interconversions modulate activity of Escherichia coli ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

The three-dimensional structure of mammalian ribonucleotide reductase protein R2 reveals a more-accessible iron-radical site than Escherichia coli R2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Crystal structural studies of changes in the native dinuclear iron center of ribonucleotide reductase protein R2 from mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

2.6 Å X-ray Crystal Structure of Human p53R2, a p53-Inducible Ribonucleotide Reductase,

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Radical initiation in the class I ribonucleotide reductase: long-range proton-coupled electron transfer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Different types of biological proton transfer reactions studied by quantum chemical methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Proton-coupled electron transfer in biology: results from synergistic studies in natural and model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

The involvement of Arg265 of mouse ribonucleotide reductase R2 protein in proton transfer and catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Spectroscopic studies of the iron and manganese reconstituted tyrosyl radical in Bacillus cereus ribonucleotide reductase R2 protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

DNA building blocks: keeping control of manufacture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

The structural gene for the M1 subunit of ribonucleotide reductase maps to chromosome 11, band p15, in human and to chromosome 7 in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase M2 subunit sequences mapped to four different chromosomal sites in humans and mice: functional locus identified by its amplification in hydroxyurea-resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

S-Phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Mouse ribonucleotide reductase R2 protein: a new target for anaphase-promoting complex-Cdh1-mediated proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

S Phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

p53 sends nucleotides to repair DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase and mitochondrial DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Comprehensive model for allosteric regulation of mammalian ribonucleotide reductase: refinements and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

On model ensemble analyses of nonmonotonic data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Tangled up in knots: structures of inactivated forms of E. coli class Ia ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Enzymatically active mammalian ribonucleotide reductase exists primarily as an alpha6beta2 octamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

The ribonucleotide reductase subunit M2B subcellular localization and functional importance for DNA replication in physiological growth of KB cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Dif1 controls subcellular localization of ribonucleotide reductase by mediating nuclear import of the R2 subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Function and regulation of yeast ribonucleotide reductase: cell cycle, genotoxic stress, and iron bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase activity is coupled to DNA synthesis via proliferating cell nuclear antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Inhibition of human cancer cell growth by inducible expression of human ribonucleotide reductase antisense cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

RRM1-induced metastasis suppression through PTEN-regulated pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

p53R2 is a prognostic factor of melanoma and regulates proliferation and chemosensitivity of melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase as a chemotherapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Mechanisms of apoptosis induction by nucleoside analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Insight into the mechanism of inactivation of ribonucleotide reductase by gemcitabine 5'-diphosphate in the presence or absence of reductant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Effect of dose regimen on the toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC) in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

High-dose cytarabine (HD araC) in the treatment of leukemias: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Cellular and clinical pharmacology of fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

The role of clofarabine in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Hydroxyurea: a key player in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase inhibition by p-alkoxyphenols studied by molecular docking and molecular dynamics simulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Peptide inhibitors of mammalian ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

1H NMR studies of mouse ribonucleotide reductase: the R2 protein carboxyl-terminal tail, essential for subunit interaction, is highly flexible but becomes rigid in the presence of protein R1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.840293